IL-33/ST2 modulation therapy represents an emerging immunomodulatory approach for treating neurodegenerative diseases. Interleukin-33 (IL-33) is a member of the IL-1 family cytokine superfamily that functions as an alarmin — released upon cell damage to initiate protective immune responses[1]. The IL-33/ST2 (IL-33 receptor) signaling axis plays complex roles in neuroinflammation, with both beneficial and pathogenic effects depending on disease context and stage.
IL-33 is constitutively expressed in the central nervous system, particularly in:
IL-33 acts as a dual-function cytokine:
The ST2 receptor (encoded by IL1RL1) exists in two forms:
Signaling pathways activated by IL-33/ST2:
IL-33/ST2 signaling exerts context-dependent effects on neuroinflammation:
Pro-inflammatory effects:
Anti-inflammatory effects:
Multiple preclinical studies demonstrate potential therapeutic benefits:
IL-33/ST2 modulation therapy remains in preclinical development for neurodegenerative diseases. No clinical trials have yet evaluated IL-33-based therapies specifically for AD, PD, or ALS.
IL-33 Agonists:
ST2 Antagonists:
Preclinical toxicology in rodent models shows:
Cayrol, C. & Girard, J.P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Allergy. 2009. ↩︎
Gadina, M. & Schwartz, G. IL-33 as a novel therapeutic target. Nature Reviews Rheumatology. 2012. ↩︎
Liu, Y. et al. IL-33 ameliorates Alzheimer's disease pathology by enhancing microglial phagocytosis of amyloid. Scientific Reports. 2019. ↩︎
Xiong, Z. et al. IL-33 improves cognitive function and reduces neuroinflammation in APP/PS1 mice. Journal of Neuroinflammation. 2020. ↩︎